Detalles de la búsqueda
1.
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
Br J Haematol
; 176(5): 783-795, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28005265
2.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Lancet
; 388(10043): 488-97, 2016 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-27291997
3.
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Br J Cancer
; 114(6): 669-79, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26978007
4.
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
Cancer Med
; 9(3): 882-893, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31821732
5.
Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
Cancer Chemother Pharmacol
; 83(1): 191-199, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30406840
6.
Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Clin Pharmacokinet
; 57(3): 355-365, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28620891
7.
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.
Clin Pharmacokinet
; 57(3): 335-344, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28540640
8.
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
Lung Cancer
; 111: 108-115, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28838379
9.
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res
; 22(23): 5688-5695, 2016 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27287072
10.
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Cancer Discov
; 6(7): 740-53, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27217383
11.
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
Leuk Lymphoma
; 56(1): 42-8, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24717109
12.
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Clin Cancer Res
; 20(14): 3763-74, 2014 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24850847
13.
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.
Mol Cancer Ther
; 13(6): 1442-56, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24688048
14.
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
Clin Cancer Res
; 18(5): 1395-403, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22223529
Resultados
1 -
14
de 14
1
Próxima >
>>